Drug reference

Umeclidinium

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 285

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Maintenance treatment of chronic obstructive pulmonary disease ▶BY INHALATION OF POWDER ▶Adult: 55 micrograms once daily DOSE EQUIVALENCE AND CONVERSION ▶Each 65 microgram inhalation of umeclidinium bromide delivers 55 micrograms of umeclidinium.

PDF page 285

Cautions

Cardiac disorders (particularly cardiac rhythm disorders)

PDF page 285

Safety

Interactions

→Appendix 1: umeclidinium

PDF page 285

Side Effects

▶Uncommon Taste altered ▶Rare or very rare Eye pain

PDF page 285

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 285

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 285

Hepatic Impairment

Manufacturer advises caution in Respiratory system severe impairment (no information available).

PDF page 285

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Inhalation powder ▶Incruse Ellipta (GlaxoSmithKline UK Ltd) A Umeclidinium bromide 65 microgram per 1 dose Incruse Ellipta 55micrograms/dose dry powder inhaler | 30 dose P £27.50 DT = £27.50 Combinations available: Fluticasone with umeclidinium and vilanterol, p. 279

PDF page 285

Clinical care

Patient And Carer Advice

Patient or carers should be given advice on appropriate inhaler technique.

PDF page 285

Dose text by age group

Adult

55 micrograms once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 285

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Umeclidinium

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 285

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 285

Cautions

Cardiac disorders (particularly cardiac rhythm disorders)

PDF page 285

Safety

Interactions

→Appendix 1: umeclidinium

PDF page 285

Side Effects

▶Uncommon Taste altered ▶Rare or very rare Eye pain

PDF page 285

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 285

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 285

Hepatic Impairment

Manufacturer advises caution in Respiratory system severe impairment (no information available).

PDF page 285

Dose and formulations

Medicinal Forms

PDF page 285

Clinical care

Patient And Carer Advice

Patient or carers should be given advice on appropriate inhaler technique.

PDF page 285

Dose text by age group

Adult

55 micrograms once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 285

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.